Down 14.5%, Is Pfizer Stock a Screaming Buy?
As the major U.S. stock indices fell into bear territory in 2022, big pharma stocks quickly became an oasis for nervous investors -- in many cases thanks to their largely recession-proof business models, reliable cash flows, and dependable quarterly dividends.
AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), Eli Lilly (NYSE: LLY), and Merck (NYSE: MRK) all trounced the broader markets last year:
Source Fool.com